Caribou Biosciences, Inc.

For the period ended Sep 30, 2026. Filed Nov 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 5, 2026

CRBU$0.41-2.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2026	2025	2026	2025
Licensing and other third-party revenue (including zero from a related party for each of the three- and nine-month periods ended September 30, 2026, and $622 and $1,865 from a related party for the three and nine months ended September 30, 2025, respectively)	$1,607	$2,198	$5,503	$7,218
Operating expenses:
Research and development	21,349	22,401	60,902	85,624
General and administrative	7,900	9,197	23,862	29,335
Impairment charges	—	—	—	12,150
Total operating expenses	29,249	31,598	84,764	127,109
Loss from operations	(27,642)	(29,400)	(79,261)	(119,891)
Other income (expense):
Impairment of equity investment	—	—	—	(9,158)
Other income, net	1,030	1,852	3,282	7,412
Total other income (expense)	1,030	1,852	3,282	(1,746)
Net loss	(26,612)	(27,548)	(75,979)	(121,637)
Other comprehensive (loss) income
Net unrealized (loss) gain on available-for-sale marketable securities, net of tax	(9)	53	(183)	(162)
Net comprehensive loss	$(26,621)	$(27,495)	$(76,162)	$(121,799)
Net loss per share, basic and diluted	$(0.25)	$(0.30)	$(0.75)	$(1.31)
Weighted-average common shares outstanding, basic and diluted	107,535,856	93,293,099	101,503,853	93,002,678

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.